Loseasonique is owned by Teva Branded Pharm.
Loseasonique contains Ethinyl Estradiol; Levonorgestrel.
Loseasonique has a total of 3 drug patents out of which 0 drug patents have expired.
Loseasonique was authorised for market use on 24 October, 2008.
Loseasonique is available in tablet;oral dosage forms.
Loseasonique can be used as prevention of pregnancy.
The generics of Loseasonique are possible to be released after 05 December, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7615545||TEVA BRANDED PHARM||Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology|| |
(2 months from now)
|US7858605||TEVA BRANDED PHARM||Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology|| |
(3 months from now)
|US7855190||TEVA BRANDED PHARM||Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration|| |
(5 years from now)
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 24 October, 2008
Treatment: Prevention of pregnancy
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic